Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;14(2):PCC.11r01222.
doi: 10.4088/PCC.11r01222. Epub 2012 Mar 22.

Prazosin for the treatment of nightmares related to posttraumatic stress disorder: a review of the literature

Steven M Hudson  1 , Travis E Whiteside, Raymond A Lorenz, Kurt A Wargo
Affiliations

Prazosin for the treatment of nightmares related to posttraumatic stress disorder: a review of the literature

Steven M Hudson et al. Prim Care Companion CNS Disord. 2012.

Abstract

Background: Posttraumatic stress disorder (PTSD) is a psychiatric disorder with symptoms that include insomnia due to hyperarousal and recurring nightmares. These symptoms are believed to be due to a conditioned response that is regulated by norepinephrine. Prazosin, an α(1) antagonist, can decrease levels of norepinephrine in the central nervous system, thereby reducing nightmares related to PTSD.

Data sources: A literature search was conducted for all studies evaluating the effectiveness of prazosin as therapy for nightmare symptoms of PTSD. MEDLINE was utilized to identify all English-language studies published between 1966 and March 2011. Keywords searched included prazosin, PTSD, and nightmares.

Results: Eleven studies were identified, including 4 open-label trials, 4 retrospective chart reviews, and 3 placebo-controlled trials. Prazosin demonstrated favorable clinical efficacy and was found to be safe for relieving PTSD-associated nightmares.

Conclusions: Current data indicate that prazosin is an effective agent for the treatment of nightmares associated with PTSD. However, the data are limited by small study sizes, lack of diversified investigators, and lack of regional diversity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000. pp. 429–484.
    1. Kirkwood CK, Makela EH, Wells BG. CH 74: Anxiety disorders II: posttraumatic stress disorder and obsessive-compulsive disorder. In: DiPiro J, Talbert R, Yee G, et al., editors. Pharmacotherapy, A Pathophysiological Approach. 7th Edition. New York, NY: McGraw-Hill Companies, Inc; 2008. pp. 1179–1184.
    1. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048–1060. - PubMed
    1. Pitman RK, Delahanty DL. Conceptually driven pharmacologic approaches to acute trauma. CNS Spectr. 2005;10(2):99–106. - PubMed
    1. Yehuda R. Risk and resilience in posttraumatic stress disorder. J Clin Psychiatry. 2004;65(suppl 1):29–36. - PubMed